Skip to main content

imzokitug

Generic: Imzokitug

imzokitug: 3 clinical trials tracked.

imzokitug evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about imzokitug, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trials (3)

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764·Phase 2·BMY
Recruiting

Primary endpoint: Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)

InterventionalRandomizedopen160 targetStarted 2026-08Completion 2030-0950 sites · Argentina, Australia, Brazil, Chile…Bristol-Myers Squibb

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

NCT07011550·Phase 2·ENTA
Suspended

Primary endpoint: Safety and adverse events (AEs)

Interventionalopen7 targetStarted 2025-08Completion 2030-071 site · United StatesM.D. Anderson Cancer Center

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709·Phase 1/Phase 2·BMY
Recruiting

Primary endpoint: Incidence of adverse events (AEs)

InterventionalRandomizedopen1,109 targetStarted 2021-05Completion 2031-0847 sites · Australia, Canada, Germany, Israel…Bristol-Myers Squibb